Martingale Asset Management’s Royalty Pharma RPRX Stock Holding History

Martingale Asset Management’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$335K	Sell	5,969 -3,950	-40%	-$206K	0.01%	736
2026 Q1	$476K	Buy	+9,919	New	+$434K	0.01%	651
2025 Q4	–	Sell	-13,919	Closed	-$491K	–	840
2025 Q3	$491K	Sell	13,919 -20,804	-60%	-$753K	0.01%	616
2025 Q2	$1.25M	Buy	34,723 +20,709	+148%	+$686K	0.03%	415
2025 Q1	$436K	Buy	+14,014	New	+$444K	0.01%	623
2024 Q3	–	Sell	-11,818	Closed	-$312K	–	835
2024 Q2	$312K	Buy	11,818 +1,013	+9%	+$28.1K	0.01%	688
2024 Q1	$328K	Buy	+10,805	New	+$319K	0.01%	694

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Martingale Asset Management's RPRX Position: Q2 2026 in Review

Martingale Asset Management reduced its Royalty Pharma (RPRX) stake by 40% in Q2 2026, selling an estimated $206K and leaving 5,969 shares worth $335K. The position accounts for 0.01% of the portfolio, ranked #736.

Martingale Asset Management first reported a position in RPRX in Q1 2024 and has held it in 7 quarters since. The position peaked at $1.25M in Q2 2025. 643 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

Martingale Asset Management held 5,969 shares of Royalty Pharma worth $335K as of Q2 2026.
Martingale Asset Management sold 3,950 Royalty Pharma shares in Q2 2026, an estimated $206K.
Royalty Pharma made up 0.01% of Martingale Asset Management's portfolio in Q2 2026, its #736 holding.
Martingale Asset Management first reported a position in Royalty Pharma in Q1 2024 and has held it in 7 quarters since.
Martingale Asset Management's Royalty Pharma position peaked at $1.25M in Q2 2025.
643 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Martingale Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.